肝癌电子杂志 ›› 2024, Vol. 11 ›› Issue (3): 1-13.
• 指南与共识 • 下一篇
中国医疗保健国际交流促进会转移肿瘤治疗学分会, 中国医疗保健国际交流促进会肝脏肿瘤学分会, 中国医疗保健国际交流促进会放射治疗学分会, 中国医疗保健国际交流促进会消化肿瘤综合诊疗学分会, 中国医疗保健国际交流促进会肿瘤免疫治疗学分会, 中国医疗保健国际交流促进会神经内分泌肿瘤学分会
收稿日期:2024-04-10
出版日期:2024-09-30
发布日期:2024-11-21
通讯作者:
蔡建强,Email：caijianqiang@cicams.ac.cn
基金资助:
Received:2024-04-10
Online:2024-09-30
Published:2024-11-21
中国医疗保健国际交流促进会转移肿瘤治疗学分会, 中国医疗保健国际交流促进会肝脏肿瘤学分会, 中国医疗保健国际交流促进会放射治疗学分会, 中国医疗保健国际交流促进会消化肿瘤综合诊疗学分会, 中国医疗保健国际交流促进会肿瘤免疫治疗学分会, 中国医疗保健国际交流促进会神经内分泌肿瘤学分会. 结直肠癌肝转移MDT诊治中国专家共识（2024版）[J]. 肝癌电子杂志, 2024, 11(3): 1-13.
| [1] XIA C F, DONG X S, LI H, et al.Cancer statistics in China and United States, 2022: profiles, trends, and determinants[J]. Chin Med J (Engl), 2022, 135(5): 584-590. [2] 郑荣寿, 陈茹, 韩冰峰, 等. 2022年中国恶性肿瘤流行情况分析[J] . 中华肿瘤杂志, 2024, 46(3) : 221-231. [3] ENGSTRAND J, NILSSON H, STRÖMBERG C, et al. Colorectal cancer liver metastases-a population-based study on incidence, management and survival[J]. BMC Cancer, 2018, 18(1): 78. [4] HONG Y S, SONG S Y, LEE S I, et al.A phase Ⅱ trial of capecitabine in previously untreated patients with advanced and/or metastatic gastric cancer[J]. Ann Oncol, 2004, 15(9): 1344-1347. [5] STEWART C L, WARNER S, ITO K, et al.Cytoreduction for colorectal metastases: liver, lung peritoneum, lymph nodes, bone, brain. When does it palliate, prolong survival, and potentially cure?[J]. Curr Probl Surg, 2018, 55(9): 330-379. [6] CHEN Q, DENG Y, CHEN J, et al.Impact of postoperative infectious complications on long-term outcomes for patients undergoing simultaneous resection for colorectal cancer liver metastases: a propensity score matching analysis[J]. Front Oncol, 2022, 11: 793653. [7] MARGONIS G A, SERGENTANIS T N, NTANASIS-STATHOPOULOS I, et al.Impact of surgical margin width on recurrence and overall survival following R0 hepatic resection of colorectal metastases: a systematic review and Meta-analysis[J]. Ann Surg, 2018, 267(6): 1047-1055. [8] VIBERT E, CANEDO L, ADAM R.Strategies to treat primary unresectable colorectal liver metastases[J]. Semin Oncol, 2005, 32(6 Suppl 8): 33-39. [9] BASSO M, CORALLO S, CALEGARI M, et al.The impact of multidisciplinary team management on outcome of hepatic resection in liver-limited colorectal metastases[J].Sci Rep, 2020, 10(1): 10871. [10] LI X, CHEN Q, BI X, et al.Effects of multidisciplinary team on the outcomes of colorectal cancer patients with liver metastases[J]. Ann Palliat Med, 2020, 9(5): 2741-2748. [11] JOHARATNAM-HOGAN N, WILSON W, SHIU K, et al.Multimodal treatment in metastatic colorectal cancer (mCRC) improves outcomes-The University College London Hospital (UCLH) experience[J]. Cancers (Basel), 2020, 12(12): 3545. [12] MILANA F, FAMULARO S, LUBERTO A, et al.Multidisciplinary tumor board in the management of patients with colorectal liver metastases: a single-center review of 847 patients[J]. Cancers (Basel), 2022, 14(16): 3952. [13] CHO J Y, LEE Y J, HAN H S, et al.Role of gadoxetic acid-enhanced magnetic resonance imaging in the preoperative evaluation of small hepatic lesions in patients with colorectal cancer[J]. World J Surg, 2015, 39(5): 1161-1166. [14] EIBER M, FINGERLE A A, BRUGEL M, et al.Detection and classification of focal liver lesions in patients with colorectal cancer: retrospective comparison of diffusion-weighted MR imaging and multi-slice CT[J]. Eur J Radiol, 2012, 81(4): 683-691. [15] YU M H, LEE J M, HUR B Y, et al.Gadoxetic acid-enhanced MRI and diffusion-weighted imaging for the detection of colorectal liver metastases after neoadjuvant chemotherapy[J]. Eur Radiol, 2015, 25(8): 2428-2436. [16] ROJAS LLIMPE F L, DI FABIO F, ERCOLANI G, et al. Imaging in resectable colorectal liver metastasis patients with or without preoperative chemotherapy: results of the PROMETEO-01 study[J]. Br J Cancer, 2014, 111(4): 667-673. [17] JHAVERI K S, FISCHER S E, HOSSEINI-NIK H, et al.Prospective comparison of gadoxetic acid-enhanced liver MRI and contRASt-enhanced CT with histopathological correlation for preoperative detection of colorectal liver metastases following chemotherapy and potential impact on surgical plan[J]. HPB (Oxford), 2017, 19(11): 992-1000. [18] ZECH C J, KORPRAPHONG P, HUPPERTZ A, et al.Randomized multicentre trial of gadoxetic acid-enhanced MRI versus conventional MRI or CT in the staging of colorectal cancer liver metastases[J]. Br J Surg, 2014, 101(6): 613-621. [19] ASATO N, TSURUSAKI M, SOFUE K, et al.Comparison of gadoxetic acid-enhanced dynamic MR imaging and contrast-enhanced computed tomography for preoperative evaluation of colorectal liver metastases[J]. Jpn J Radiol, 2017, 35(4): 197-205. [20] CHOI S H, KIM S Y, PARK S H, et al.Diagnostic performance of CT, gadoxetate disodium-enhanced MRI, and PET/CT for the diagnosis of colorectal liver metastasis: systematic review and meta-analysis[J]. J Magn Reson Imaging, 2018, 47(5): 1237-1250. [21] KIM H J, LEE S S, BYUN J H, et al.Incremental value of liver MR imaging in patients with potentially curable colorectal hepatic metastasis detected at CT: a prospective comparison of diffusion-weighted imaging, gadoxetic acid-enhanced MR imaging, and a combination of both MR techniques[J]. Radiology, 2015, 274(3): 712-722. [22] KIM C, KIM S Y, KIM M J, et al.Clinical impact of preoperative liver MRI in the evaluation of synchronous liver metastasis of colon cancer[J]. Eur Radiol, 2018, 28(10): 4234-4242. [23] GORGEC B, HANSEN IS, KEMMERICH G, et al.MRI in addition to CT in patients scheduled for local therapy of colorectal liver metastases (CAMINO): an international, multicentre, prospective, diagnostic accuracy trial[J]. Lancet Oncol, 2024, 25: 137-146. [24] JE I J, TUTEIN NOLTHENIUS C J, KUIPERS E J, et al. CT-colonography vs. colonoscopy for detection of high-risk sessile serrated polyps[J]. Am J Gastroenterol, 2016, 111(4): 516-522. [25] ATKIN W, DADSWELL E, WOOLDRAGE K, et al.Computed tomographic colonography versus colonoscopy for investigation of patients with symptoms suggestive of colorectal cancer (SIGGAR): a multicentre randomised trial[J]. Lancet, 2013, 381(9873): 1194-1202. [26] STOOP E M, DE HAAN M C, DE WIJKERSLOOTH T R, et al. Participation and yield of colonoscopy versus non-cathartic CT colonography in population-based screening for colorectal cancer: a randomised controlled trial[J]. Lancet Oncol, 2012, 13(1): 55-64. [27] MARI F S, NIGRI G, PANCALDI A, et al.Role of CT angiography with three-dimensional reconstruction of mesenteric vessels in laparoscopic colorectal resections: a randomized controlled trial[J]. Surg Endosc, 2013, 27(6): 2058-2067. [28] SATO K, TANAKA T, SATO J, et al.Usefulness of preoperative CT colonography for colon cancer[J]. Asian J Surg, 2017, 40(6): 438-443. [29] GROUP M S.Extramural depth of tumor invasion at thin-section MR in patients with rectal cancer: results of the MERCURY study[J]. Radiology, 2007, 243(1): 132-139. [30] BERNSTEIN T E, ENDRESETH B H, ROMUNDSTAD P, et al.Circumferential resection margin as a prognostic factor in rectal cancer[J]. Br J Surg, 2009, 96(11): 1348-1357. [31] MAIZLIN Z V, BROWN J A, SO G, et al.Can CT replace MRI in preoperative assessment of the circumferential resection margin in rectal cancer?[J]. Dis Colon Rectum, 2010, 53(3): 308-314. [32] SMITH N J, BARBACHANO Y, NORMAN A R, et al.Prognostic significance of magnetic resonance imaging-detected extramural vascular invasion in rectal cancer[J]. Br J Surg, 2008, 95(2): 229-236. [33] VAN KESSEL C S, BUCKENS C F, VAN DEN BOSCH M A, et al. Preoperative imaging of colorectal liver metastases after neoadjuvant chemotherapy: a meta-analysis[J]. Ann Surg Oncol, 2012, 19(9): 2805-2813. [34] 李卫华, 李研, 郭蕾, 等. 基于二代测序技术比较结直肠癌原发灶与同时或异时性肝转移灶基因突变状态的异同[J/CD]. 肝癌电子杂志, 2020, 7(1): 39-44. [35] LI W, QIU T, GUO L, et al.Major challenges related to tumor biological characteristics in accurate mutation detection of colorectal cancer by next-generation sequencing[J]. Cancer Lett, 2017, 410: 92-99. [36] LI W, QIU T, GUO L, et al.NGS-based oncogenic mutations analysis in advanced colorectal cancer patients improves targeted therapy prediction[J]. Pathol Res Pract, 2019, 215(3): 483-489. [37] CIARDIELLO D, MAIORANO BA, MARTINELLI E.TargetingKRAS(G12C) in colorectal cancer: the beginning of a new era[J]. ESMO Open, 2023, 8(1): 100745. [38] YAO Z, YAEGER R, RODRIK-OUTMEZGUINE V S, et al. Tumours with class 3BRAFmutants are sensitive to the inhibition of activatedRAS[J]. Nature, 2017, 548(7666): 234-238. [39] SINICROPE F A, SHI Q, ALLEGRA C J, et al.Association of DNA mismatch repair and mutations inBRAFandKRASwith survival after recurrence in stage Ⅲ colon cancers: a secondary analysis of 2 randomized clinical trials[J]. JAMA Oncol, 2017, 3(4): 472-480. [40] STRICKLER J H, YOSHINO T, GRAHAM R P, et al.Diagnosis and treatment of ERBB2-positive metastatic colorectal cancer: a review[J]. JAMA Oncol, 2022, 8(5): 760-769. [41] KLINK AJ, KAVATI A, GASSAMA A, et al.Treatment patterns of real-world patients with TRK fusion cancer treated by US community oncologists[J]. Target Oncol, 2022, 17(5): 549-561. [42] MOTTA R, CABEZAS-CAMARERO S, TORRES-MATTOS C, et al.Immunotherapy in microsatellite instability metastatic colorectal cancer: current status and future perspectives[J]. J Clin Transl Res, 2021, 7(4): 511-522. [43] 中国抗癌协会肿瘤病理专业委员会, 中华医学会肿瘤学分会肺癌专家委员会, 国家病理质控中心. 非小细胞肺癌融合基因检测临床实践中国专家共识(2023版)[J]. 中华病理学杂志, 2023, 52(6): 565-573. [44] DONG L, JIN X, WANG W, et al.Distinct clinical phenotype and genetic testing strategy for Lynch syndrome in China based on a large colorectal cancer cohort[J]. Int J Cancer, 2020, 146(11): 3077-3086. [45] DONG L, ZOU S, JIN X, et al.Cytoplasmic MSH2 related to genomic deletions in the MSH2/EPCAM genes in colorectal cancer patients with suspected lynch syndrome[J]. Front Oncol, 2021, 11: 627460. [46] MA X, DONG L, LIU X, et al.POLE/POLD1 mutation and tumor immunotherapy[J]. J Exp Clin Cancer Res, 2022, 41(1): 216. [47] MOSELE F, REMON J, MATEO J, et al.Recommendations for the use of next-generation sequencing (NGS) for patients with metastatic cancers: a report from the ESMO precision medicine working group[J]. Ann Oncol, 2020, 31(11): 1491-1505. [48] BENTREM D, DEMATTEO R, BLUMGART L.Surgical therapy for metastatic disease to the liver[J]. Ann Rev Med, 2005, 56: 139-156. [49] AKGÜL Ö, ÇETINKAYA E, ERSÖ Z, et al. Role of surgery in colorectal cancer liver metastases[J]. World J Gastroenterol, 2014, 20(20): 6113-6122. [50] MAYO S, PAWLIK T.Current management of colorectal hepatic metastasis[J]. Expert Rev Gastroenterol Hepatol, 2009, 3(2): 131-144. [51] T EŠKA V, BRŮHA J, SKALICKÝ T, et al. Radiofrequency ablation of colorectal liver metastases[J]. Rozhl Chir, 2019, 98(10): 399-403. [52] DEXIANG Z, LI R, YE W, et al.Outcome of patients with colorectal liver metastasis: analysis of 1,613 consecutive cases[J]. Ann Surg Oncol, 2012, 19(9): 2860-2868. [53] ADAM R, KITANO Y.Multidisciplinary approach of liver metastases from colorectal cancer[J]. Ann Gastroenterol Surg, 2019, 3(1): 50-56. [54] TIMMERMAN R, BIZEKIS C, PASS H, et al.Local surgical, ablative, and radiation treatment of metastases[J]. CA Cancer J Clin, 2009, 59(3): 145-170. [55] SHARMA S, CAMCI C, JABBOUR N.Management of hepatic metastasis from colorectal cancers: an update[J]. J Hepatobiliary Pancreat Surg, 2008, 15(6): 570-580. [56] KHAN A, GARCIA-AROZ S, ANSARI M, et al.Assessment and optimization of liver volume before major hepatic resection: current guidelines and a narrative review[J]. Int J Surg, 2018, 52: 74-81. [57] YAN T, PADANG R, XIA H, et al.Management of involved or close resection margins in 120 patients with colorectal liver metastases: edge cryotherapy can achieve long-term survival[J]. Am J Surg, 2006, 191(6): 735-742. [58] TURRINI O, VIRET F, GUIRAMAND J, et al.Strategies for the treatment of synchronous liver metastasis[J]. Eur J Surg Oncol, 2007, 33(6): 735-740. [59] WU Y, MAO A, WANG H, et al.Association of simultaneous vs delayed resection of liver metastasis with complications and survival among adults with colorectal cancer[J]. JAMA Netw Open, 2022, 5(9): e2231956. [60] NORDLINGER B, SORBYE H, GLIMELIUS B, et al.Perioperative FOLFOX4 chemotherapy and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC 40983): long-term results of a randomised, controlled, phase 3 trial[J]. Lancet Oncol, 2013, 14(12): 1208-1215. [61] LOGAN J, HUBER K, DIPETRILLO T, et al.Patterns of care of radiation therapy in patients with stage Ⅳ rectal cancer: a surveillance, epidemiology, and end results analysis of patients from 2004 to 2009[J]. Cancer, 2014, 120(5): 731-737. [62] TANAKA K, ADAM R, SHIMADA H, et al.Role of neoadjuvant chemotherapy in the treatment of multiple colorectal metastases to the liver[J]. Br J Surg, 2003, 90(8): 963-969. [63] GRUENBERGER B, SCHEITHAUER W, PUNZENGRUBER R, et al.Importance of response to neoadjuvant chemotherapy in potentially curable colorectal cancer liver metastases[J]. BMC Cancer, 2008, 8: 120. [64] LEHMANN K, CLAVIEN P A.Reply to letter: "chemotherapy before liver resection of colorectal metastases: friend or foe?"[J]. Ann Surg, 2015, 261(2): e36-e37. [65] BRIDGEWATER J A, PUGH S A, MAISHMAN T, et al.Systemic chemotherapy with or without cetuximab in patients with resectable colorectal liver metastasis (New EPOC): long-term results of a multicentre, randomised, controlled, phase 3 trial[J]. Lancet Oncol, 2020, 21(3): 398-411. [66] ADAM R, DE GRAMONT A, FIGUERAS J, et al.The oncosurgery approach to managing liver metastases from colorectal cancer: a multidisciplinary international consensus[J]. Oncologist, 2012, 17(10): 1225-1239. [67] ADAM R, PASCAL G, CASTAING D, et al.Tumor progression while on chemotherapy: a contraindication to liver resection for multiple colorectal metastases?[J]. Ann Surg, 2004, 240(6): 1052-1061. [68] MANN C D, METCALFE M S, LEOPARDI L N, et al.The clinical risk score: emerging as a reliable preoperative prognostic index in hepatectomy for colorectal metastases[J]. Arch Surg, 2004, 139(11): 1168-1172. [69] 吕雪琰, 毕新宇, 赵宏, 等. 新辅助化疗未达客观缓解的结直肠癌肝转移后续治疗方案的比较: 直接手术或二线化疗后手术[J]. 中华外科杂志, 2022, 60(5): 454-460. [70] SHIN S J, AHN J B, CHOI J S, et al.Implications of clinical risk score to predict outcomes of liver-confined metastasis of colorectal cancer[J]. Surg Oncol, 2012, 21(3): e125-e130. [71] PAWLIK T, SCOGGINS C, ZORZI D, et al.Effect of surgical margin status on survival and site of recurrence after hepatic resection for colorectal metastases[J]. Ann Surg, 2005, 241(5): 715-722. [72] AYEZ N, LALMAHOMED Z, EGGERMONT A, et al.Outcome of microscopic incomplete resection (R1) of colorectal liver metastases in the era of neoadjuvant chemotherapy[J]. Ann Surg Oncol, 2012, 19(5): 1618-1627. [73] PANDANABOYANA S, WHITE A, PATHAK S, et al.Impact of margin status and neoadjuvant chemotherapy on survival, recurrence after liver resection for colorectal liver metastasis[J]. Ann Surg Oncol, 2015, 22(1): 173-179. [74] LI Y, BI X, ZHAO J, et al.Simultaneous hepatic resection benefits patients with synchronous colorectal cancer liver metastases[J]. Chin J Cancer Re, 2016, 28(5): 528-535. [75] SIRIWARDENA A K, MASON J M, MULLAMITHA S, et al.Management of colorectal cancer presenting with synchronous liver metastases[J]. Nat Rev Clin Oncol, 2014, 11(8): 446-459. [76] 李星辰, 李智宇, 罗治文, 等. 结直肠癌肝转移全腹腔镜与腹腔镜辅助同期切除术的比较研究[J]. 中华肿瘤杂志, 2020, 42(5): 413-418. [77] NAKAJIMA K, TAKAHASHI S, SAITO N, et al.Predictive factors for anastomotic leakage after simultaneous resection of synchronous colorectal liver metastasis[J]. J Gastrointest Surg, 2012, 16(4): 821-827. [78] HATWELL C, BRETAGNOL F, FARGES O, et al.Laparoscopic resection of colorectal cancer facilitates simultaneous surgery of synchronous liver metastases[J]. Colorectal Dis, 2013, 15(1): e21-e28. [79] SCHNITZBAUER A, LANG S, GOESSMANN H, et al.Right portal vein ligation combined with in situ splitting induces rapid left lateral liver lobe hypertrophy enabling 2-staged extended right hepatic resection in small-for-size settings[J]. Ann Surg, 2012, 255(3): 405-414. [80] ROXBURGH C S, RICHARDS C H, MOUG S J, et al.Determinants of short- and long-term outcome in patients undergoing simultaneous resection of colorectal cancer and synchronous colorectal liver metastases[J]. Int J Colorectal Dis, 2012, 27(3): 363-369. [81] SLUPSKI M, WLODARCZYK Z, JASINSKI M, et al.Outcomes of simultaneous and delayed resections of synchronous colorectal liver metastases[J]. Can J Surg, 2009, 52(6): E241-E244. [82] DE JONG M C, VAN DAM R M, MAAS M, et al. The liver-first approach for synchronous colorectal liver metastasis: a 5-year single-centre experience[J]. HPB (Oxford), 2011, 13(10): 745-752. [83] DE JONG M C, BECKERS R C J, VAN WOERDEN V, et al. The liver-first approach for synchronous colorectal liver metastases: more than a decade of experience in a single centre[J]. HPB (Oxford), 2018, 20(7): 631-640. [84] CIROCCHI R, TRASTULLI S, BOSELLI C, et al. Radiofrequency ablation in the treatment of liver metastases from colorectal cancer[J]. Cochrane Database Syst Rev, 2012(6): CD006317. [85] HAMMILL C W, BILLINGSLEY K G, CASSERA M A, et al.Outcome after laparoscopic radiofrequency ablation of technically resectable colorectal liver metastases[J]. Ann Surg Oncol, 2011, 18(7): 1947-1954. [86] RAHBARI N N, BIRGIN E, BORK U, et al.Anterior approach vs conventional hepatectomy for resection of colorectal liver metastasis: a randomized clinical trial[J]. JAMA Surgery, 2021, 156(1): 31-40. [87] ARAUJO RL, GÖNEN M, HERMAN P. Chemotherapy for patients with colorectal liver metastases who underwent curative resection improves long-term outcomes: systematic review and meta-analysis[J]. Ann Surg Oncol, 2015, 22(9): 3070-3078. [88] ARAUJO R, GONEN M, ALLEN P, et al.Comparison between perioperative and postoperative chemotherapy after potentially curative hepatic resection for metastatic colorectal cancer[J]. Ann Surg Oncol, 2013, 20(13): 4312-4321. [89] KANEMITSU Y, SHIMIZU Y, MIZUSAWA J, et al.Hepatectomy followed by mFOLFOX6 versus hepatectomy alone for liver-only metastatic colorectal cancer (JCOG0603): a phase Ⅱ or Ⅲ randomized controlled trial[J]. J Clin Oncol, 2021, 39(34): 3789-3799. [90] GE H, ZHOU Z, LI Y, et al.Prognostic factors and individualized nomograms predicting overall survival in stage Ⅳ rectal cancer patients with different metastatic status: a SEER-based study[J]. Transl Cancer Res, 2022, 11(9): 3141-3155. [91] AGAS R A F, CO L B A, JACINTO J, et al. Neoadjuvant radiotherapy versus no radiotherapy for stage Ⅳ rectal cancer: a systematic review and meta-analysis[J]. J Gastrointest Cancer, 2018, 49(4): 389-401. [92] NCCN. NCCN Clinical Practice Guidelines in Oncology. Rectal Cancer Version 4.2023(2023)[EB/OL][2024-04-04], https://www.nccn.org/professionals/physician_gls/pdf/rectal.pdf. [93] GLYNNE-JONES R, WYRWICZ L, TIRET E, et al. Rectal cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up[J]. Ann Oncol, 2017, 28(suppl_4): iv22-iv40. [94] ALBERTS S R, HORVATH W L, STERNFELD W C, et al.Oxaliplatin, fluorouracil, and leucovorin for patients with unresectable liver-only metastases from colorectal cancer: a North Central Cancer Treatment Group phase Ⅱ study[J]. J Clin Oncol, 2005, 23(36): 9243-9249. [95] ADAM R, DELVART V, PASCAL G, et al.Rescue surgery for unresectable colorectal liver metastases downstaged by chemotherapy: a model to predict long-term survival[J]. Ann Surg, 2004, 240(4): 644-657. [96] DELAUNOIT T, ALBERTS S R, SARGENT D J, et al.Chemotherapy permits resection of metastatic colorectal cancer: experience from Intergroup N9741[J]. Ann Oncol, 2005, 16(3): 425-429. [97] FOLPRECHT G, GRUENBERGER T, BECHSTEIN W O, et al.Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial[J]. Lancet Oncol, 2010, 11(1): 38-47. [98] FOLPRECHT G, GRUENBERGER T, BECHSTEIN W, et al.Survival of patients with initially unresectable colorectal liver metastases treated with FOLFOX/cetuximab or FOLFIRI/cetuximab in a multidisciplinary concept (CELIM study)[J]. Ann Oncol, 2014, 25(5): 1018-1025. [99] YE L C, LIU T S, REN L, et al.Randomized controlled trial of cetuximab plus chemotherapy for patients withKRASwild-type unresectable colorectal liver-limited metastases[J]. J Clin Oncol, 2013, 31(16): 1931-1938. [100] PETRELLI F, BARNI S, ANTI-EGFR AGENTS FOR LIVER METASTASES. Resectability and outcome with anti-EGFR agents in patients withKRASwild-type colorectal liver-limited metastases: a meta-analysis[J]. Int J Colorectal Dis, 2012, 27(8): 997-1004. [101] FUCHS C S, MARSHALL J, MITCHELL E, et al.Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: results from the BICC-C Study[J]. J Clin Oncol, 2007, 25(30): 4779-4786. [102] HURWITZ H, FEHRENBACHER L, NOVOTNY W, et al.Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer[J]. N Engl J Med, 2004, 350(23): 2335-2342. [103] FALCONE A, RICCI S, BRUNETTI I, et al.PhaseⅢ trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nord Ovest[J]. J Clin Oncol, 2007, 25(13): 1670-1676. [104] SOUGLAKOS J, ANDROULAKIS N, SYRIGOS K, et al.FOLFOXIRI (folinic acid, 5-fluorouracil, oxaliplatin and irinotecan) vs FOLFIRI (folinic acid, 5-fluorouracil and irinotecan) as first-line treatment in metastatic colorectal cancer (MCC): a multicentre randomised phase Ⅲ trial from the Hellenic Oncology Research Group (HORG)[J]. Br J Cancer, 2006, 94(6): 798-805. [105] HU H, WANG K, HUANG M, et al.Modified FOLFOXIRI with or without cetuximab as conversion therapy in patients withRAS/BRAFwild-type unresectable liver metastases colorectal cancer: the FOCULM multicenter phase Ⅱ trial[J]. Oncologist, 2021, 26(1): e90-e98. [106] CREMOLINI C. Modified FOLFOXIRI plus panitumumab (mFOLFOXIRI/PAN) versus mFOLFOX6/PAN as initial treatment of patients with unresectableRASandBRAFwild-type metastatic colorectal cancer (mCRC): results of the phaseⅢ randomized TRIPLETE study by GONO[J]. J Clin Oncol, 2022, 40(17 Suppl): LBA3505. [107] PUNT CJA. FOLFOXIRI + bevacizumab versus FOLFOX/FOLFIRI + bevacizumab in patients with initially unresectable colorectal liver metastases (CRLM) andright-sided and/orRAS/BRAFV600E-mutated primary tumor: phaseⅢ CAIRO5 study of the Dutch Colorectal Cancer Group[J]. J Clin Oncol, 2022, 40(17 Suppl): LBA3506. [108] BOND M J G, BOLHUIS K, LOOSVELD O J L, et al. First-line systemic treatment strategies in patients with initially unresectable colorectal cancer liver metastases (CAIRO5): an open-label, multicentre, randomised, controlled, phase 3 study from the Dutch Colorectal Cancer Group[J]. Lancet Oncol, 2023, 24(7): 757-771. [109] BOND M.LBA21 FOLFOX/FOLFIRI plus either bevacizumab or panitumumab in patients with initially unresectable colorectal liver metastases (CRLM) and left-sided andRAS/BRAFV600E wild-type tumour: phase Ⅲ CAIRO5 study of the Dutch Colorectal Cancer Group[J]. Ann Oncol, 2022, 33: S1389. [110] TSUJI A.The randomized phaseⅡ study of FOLFOXIRI plus cetuximab versus FOLFOXIRI plus bevacizumab as the first-line treatment in metastatic colorectal cancer withRASwild-type tumors: the DEEPER trial (JACCRO CC-13)[J]. J Clin Oncol, 2021, 39(15 Suppl): 3501. [111] SUNAKAWA Y.Modified (m)-FOLFOXIRI plus cetuximab versus m-FOLFOXIRI plus bevacizumab as initial treatment of patients with unresectableRASandBRAFwild-type metastatic colorectal cancer: survival analysis of the phase Ⅱ randomized DEEPER trial by JACCRO[J]. J Clin Oncol, 2023, 41(4 Suppl): 120. [112] CHOTI M A.Chemotherapy-associated hepatotoxicity: do we need to be concerned?[J]. Ann Surg Oncol, 2009, 16(9): 2391-2394. [113] KISHI Y, ZORZI D, CONTRERAS C M, et al.Extended preoperative chemotherapy does not improve pathologic response and increases postoperative liver insufficiency after hepatic resection for colorectal liver metastases[J]. Ann Surg Oncol, 2010, 17(11): 2870-2876. [114] RUBBIA-BRANDT L, AUDARD V, SARTORETTI P, et al.Severe hepatic sinusoidal obstruction associated with oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer[J]. Ann Oncol, 2004, 15(3): 460-466. [115] DIAZ L A, SHIU K K, KIM T W, et al.Pembrolizumab versus chemotherapy for microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer (KEYNOTE-177): final analysis of a randomised, open-label, phase 3 study[J]. Lancet Oncol, 2022, 23(5): 659-670. [116] CHALABI M, FANCHI L F, DIJKSTRA K K, et al.Neoadjuvant immunotherapy leads to pathological responses in MMR-proficient and MMR-deficient early-stage colon cancers[J]. Nat Med, 2020, 26(4): 566-576. [117] CHALABI M, VERSCHOOR Y, VAN DEN BERG J, et al. LBA7--Neoadjuvant immune checkpoint inhibition in locally advanced MMR-deficient colon cancer: The NICHE-2 study[J]. Ann Oncol, 2022, 33: S1389. [118] ELIAS D, YOUSSEF O, SIDERIS L, et al.Evolution of missing colorectal liver metastases following inductive chemotherapy and hepatectomy[J]. J Surg Oncol, 2004, 86(1): 4-9. [119] COLUCCI G, GEBBIA V, PAOLETTI G, et al.Phase Ⅲ randomized trial of FOLFIRI versus FOLFOX4 in the treatment of advanced colorectal cancer: a multicenter study of the Gruppo Oncologico Dell'Italia Meridionale[J]. J Clin Oncol, 2005, 23(22): 4866-4875. [120] RUBBIA-BRANDT L, GIOSTRA E, BREZAULT C, et al.Importance of histological tumor response assessment in predicting the outcome in patients with colorectal liver metastases treated with neo-adjuvant chemotherapy followed by liver surgery[J]. Ann Oncol, 2007, 18(2): 299-304. [121] FALCONE A, RICCI S, BRUNETTI I, et al.Phase Ⅲ trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nord Ovest[J]. J Clin Oncol, 2007, 25(13): 1670-1676. [122] TOURNIGAND C, ANDRÉ T, ACHILLE E, et al.FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study[J]. J Clin Oncol, 2004, 22(2): 229-237. [123] CALS L, RIXE O, FRANÇOIS E, et al. Dose-finding study of weekly 24-h continuous infusion of 5-fluorouracil associated with alternating oxaliplatin or irinotecan in advanced colorectal cancer patients[J]. Ann Oncol, 2004, 15(7): 1018-1024. [124] HOCHSTER H S, HART L L, RAMANATHAN R K, et al.Safety and efficacy of oxaliplatin and fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer: results of the TREE Study[J]. J Clin Oncol, 2008, 26(21): 3523-3529. [125] KOPETZ S, YOSHINO T, KIM T, et al.BREAKWATER safety lead-in (SLI): Encorafenib (E) + cetuximab (C) + chemotherapy forBRAFV600E metastatic colorectal cancer (mCRC)[J]. J Clin Oncol, 2023, 41(4 Suppl): 119. [126] FAKIH M G, KOPETZ S, KUBOKI Y, et al.SotoRASib for previously treated colorectal cancers withKRAS(G12C) mutation (CodeBreaK100): a prespecified analysis of a single-arm, phase 2 trial[J]. Lancet Oncol, 2022, 23(1): 115-124. [127] Bekaii-Saab T S, Spira A I, Rona Y, et al. KRYSTAL-1: Updated activity and safety of adagrasib (MRTX849) in patients with unresectable or metastatic pancreatic cancer and other gastrointestinal tumors harboring aKRASG12C mutation[J]. J Clin Oncol, 2022, 40(4_suppl): 519. [128] KUBOKI Y, FAKIH M, STRICKLER J, et al.315O Sotorasib in combination with panitumumab in refractoryKRASG12C-mutated colorectal cancer: Safety and efficacy for phase Ⅰb full expansion cohort[J]. Ann Oncol, 2022, 33: S680-S681. [129] STRICKLER J H, CERCEK A, SIENA S, et al.Tucatinib plus trastuzumab for chemotherapy-refractory, HER2-positive, RAS wild-type unresectable or metastatic colorectal cancer (MOUNTAINEER): a multicentre, open-label, phase 2 study[J]. Lancet Oncol, 2023, 24(5): 496-508. [130] BLOMGREN H, LAX I, NÄSLUND I, et al. Stereotactic high dose fraction radiation therapy of extracranial tumors using an accelerator. Clinical experience of the first thirty-one patients[J]. Acta Oncol, 1995, 34(6): 861-870. [131] SHEIKH S, CHEN H, SAHGAL A, et al.An analysis of a large multi-institutional database reveals important associations between treatment parameters and clinical outcomes for stereotactic body radiotherapy (SBRT) of oligometastatic colorectal cancer[J]. Radiother Oncol, 2022, 167: 187-194. [132] JETHWA K R, JANG S, MULLIKIN T C, et al.Association of tumor genomic factors and efficacy for metastasis-directed stereotactic body radiotherapy for oligometastatic colorectal cancer[J]. Radiother Oncol, 2020, 146: 29-36. [133] FRANZESE C, COMITO T, TOSKA E, et al.Predictive factors for survival of oligometastatic colorectal cancer treated with Stereotactic body radiation therapy[J]. Radiother Oncol, 2019, 133: 220-226. [134] JOO J H, PARK J H, KIM J C, et al.Local control outcomes using stereotactic body radiation therapy for liver metastases from colorectal cancer[J]. Int J Radiat Oncol Biol Phys, 2017, 99(4): 876-883. [135] PAN C C, KAVANAGH B D, DAWSON L A, et al.Radiation-associated liver injury[J]. Int J Radiat Oncol Biol Phys, 2010, 76(3 Suppl): S94-S100. [136] KIM K, YU J I, PARK H C, et al.A phase Ⅱ trial of hypofractionated high-dose proton beam therapy for unresectable liver metastases[J]. Radiother Oncol, 2022, 176: 9-16. [137] REIG M, FORNER A, RIMOLA J, et al.BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update[J]. J Hepatol, 2022, 76(3): 681-693. [138] ZHOU J, SUN H, WANG Z, et al.Guidelines for the diagnosis and treatment of hepatocellular carcinoma (2019 edition)[J]. Liver Cancer, 2020, 9(6): 682-720. [139] CHEN L T, MARTINELLI E, CHENG A L, et al.Pan-Asian adapted ESMO clinical practice guidelines for the management of patients with intermediate and advanced/relapsed hepatocellular carcinoma: a TOS-ESMO initiative endorsed by CSCO, ISMPO, JSMO, KSMO, MOS and SSO[J]. Ann Oncol, 2020, 31(3): 334-351. [140] AMMORI J B, KEMENY N E.Regional hepatic chemotherapies in treatment of colorectal cancer metastases to the liver[J]. Semin Oncol, 2010, 37(2): 139-148. [141] BUISMAN F E, FILIPE W F, GALJART B, et al.Adjuvant intra-arterial chemotherapy for patients with resected colorectal liver metastases: a systematic review and meta-analysis[J]. HPB (Oxford), 2022, 24(3): 299-308. [142] CAO G, WANG X, CHEN H, et al.Hepatic arterial infusion chemotherapy plus regorafenib in advanced colorectal cancer: a real-world retrospective study[J]. BMC Gastroenterol, 2022, 22(1): 328. [143] FENG A W, GUO J H, GAO S, et al.A randomized phaseⅡ trial of hepatic arterial infusion of oxaliplatin plus raltitrexed versus oxaliplatin plus 5-fluorouracil for unresectable colorectal cancer liver metastases[J]. Front Oncol, 2022, 12: 913017. [144] HELMBERGER T, LUCATELLI P, PEREIRA P L, et al.Safety, feasibility and technical considerations from a prospective, observational study-CIREL: irinotecan-TACE for CRLM in 152 patients[J]. J Clin Med, 2022, 11(20): 6178. [145] ZHAO G, LIU S, ZHANG Y, et al.Irinotecan eluting beads-transarterial chemoembolization using Callispheres® microspheres is an effective and safe approach in treating unresectable colorectal cancer liver metastases[J]. Ir J Med Sci, 2022, 191(3): 1139-1145. [146] ISHIKAWA T, IMAI M, SATO R, et al.Prognostic value of TACE with irinotecan-loaded drug-eluting beads (DEBIRI) in patients with liver metastases from unresectable colorectal cancer[J]. Anticancer Res, 2023, 43(8): 3647-3651. [147] MARAJ T, MIRRAHIMI A, DEY C.Survival of patients with colorectal liver metastases after transarterial chemoembolization using irinotecan-eluting microspheres: a single-center retrospective analysis comparing RECIST 1.1 and choi criteria[J]. J Vasc Interv Radiol, 2023, 34(6): 983-990. [148] CAO F, ZHENG J, LUO J, et al.Treatment efficacy and safety of regorafenib plus drug-eluting beads-transarterial chemoembolization versus regorafenib monotherapy in colorectal cancer liver metastasis patients who fail standard treatment regimens[J]. J Cancer Res Clin Oncol, 2021, 147(10): 2993-3002. [149] LU H, ZHENG C, FAN L, et al.Efficacy and safety of TACE combined with regorafenib versus TACE in the third-line treatment of colorectal liver metastases[J]. J Oncol, 2022: 5366011. [150] FRIEDRICH S, BUSCH F, JONCZYK M, et al. Combined CT-guided high-dose-rate brachytherapy (CT-HDRBT) andtransarterial chemoembolization with irinotecan-loaded microspheres improve local tumor control and progression-free survival in patients with unresectable colorectal liver metastases compared with mono-CT-HDRBT[J]. Clin Pharmacol Ther, 2024. Online ahead of print. [151] SHI Q, WANG F, DU N, et al.Microwave ablation combined with lipiodol-microsphere mixed or conventional transarterial chemoembolization for the treatment of colorectal liver metastases: a retrospective study[J]. Clin Res Hepatol Gastroenterol, 2022, 46(7): 101986. [152] MULCAHY M F, MAHVASH A, PRACHT M, et al.Radioembolization with chemotherapy for colorectal liver metastases: a randomized, open-label, international, multicenter, phaseⅢ trial[J]. J Clin Oncol, 2021, 39(35): 3897-3907. [153] VAN HAZEL G A, HEINEMANN V, SHARMA N K, et al. SIRFLOX: randomized phaseⅢ trial comparing first-line mFOLFOX6 (plus or minus bevacizumab) versus mFOLFOX6 (plus or minus bevacizumab) plus selective internal radiation therapy in patients with metastatic colorectal cancer[J]. J Clin Oncol, 2016, 34(15): 1723-1731. [154] MOCELLIN S, PASQUALI S, NITTI D. Fluoropyrimidine-HAI (hepatic arterial infusion) versus systemic chemotherapy (SCT) for unresectable liver metastases from colorectal cancer[J]. Cochrane Database Syst Rev, 2009(3): CD007823. [155] CHAN D L, ALZAHRANI N A, MORRIS D L, et al.Systematic review and Meta-analysis of hepatic arterial infusion chemotherapy as bridging therapy for colorectal liver metastases[J/OL]. Surg Oncol, 2015, 24(3): 162-171. [156] D'ANGELICA M I, CORREA-GALLEGO C, PATY P B, et al. Phase Ⅱ trial of hepatic artery infusional and systemic chemotherapy for patients with unresectable hepatic metastases from colorectal cancer: conversion to resection and long-term outcomes[J]. Ann Surg, 2015, 261(2): 353-360. [157] MCAULIFFE J C, QADAN M, D’ANGELICA M I. Hepatic resection, hepatic arterial infusion pump therapy, and genetic biomarkers in the management of hepatic metastases from colorectal cancer[J]. J Gastrointest Oncol, 2015, 6(6): 699-708. [158] LIU D M, THAKOR A S, BAERLOCHER M, et al.A review of conventional and drug-eluting chemoembolization in the treatment of colorectal liver metastases: principles and proof[J]. Future Oncol, 2015, 11(9): 1421-1428. [159] PATKAR S, CHOPDE A, SHETTY N, et al.Multimodality liver directed treatment for colorectal liver metastasis: Array of complementary options can improve outcomes-a single centre experience from India[J]. Front Oncol, 2023, 13: 1073311. [160] LOCKER G Y, HAMILTON S, HARRIS J, et al.ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer[J]. J Clin Oncol, 2006, 24(33): 5313-5327. [161] DESCH C E, BENSON A B, SOMERFIELD M R, et al.American Society of Clinical Oncology. Colorectal cancer surveillance: 2005 update of an American Society of Clinical Oncology practice guideliner[J]. J Clin Oncol, 2005, 23(33): 8512-8519. [162] REX D K, KAHI C J, LEVIN B, et al.Guidelines for colonoscopy surveillance after cancer resection: a consensus update by the American Cancer Society and the US Multi-Society Task Force on Colorectal Cancer[J]. Gastroenterology, 2006, 130(6): 1865-1871. [163] KAHI C J, BOLAND C R, DOMINITZ J A, et al.Colonoscopy surveillance after colorectal cancer resection: recommendations of the US Multi-Society Task Force on Colorectal Cancer[J]. Am J Gastroenterol, 2016, 111(3): 337-346. |
| No related articles found! |
| 阅读次数 | ||||||
|
全文 |
|
|||||
|
摘要 |
|
|||||
